# Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer

> **NCT01480154** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 62 (actual)

## Conditions studied

- Advanced Malignant Solid Neoplasm
- Stage III Cutaneous Melanoma AJCC v7
- Stage III Prostate Cancer AJCC v7
- Stage III Renal Cell Cancer AJCC v7
- Stage IIIA Cutaneous Melanoma AJCC v7
- Stage IIIB Cutaneous Melanoma AJCC v7
- Stage IIIC Cutaneous Melanoma AJCC v7
- Stage IV Cutaneous Melanoma AJCC v6 and v7
- Stage IV Prostate Cancer AJCC v7
- Stage IV Renal Cell Cancer AJCC v7

## Interventions

- **DRUG:** Akt Inhibitor MK2206
- **DRUG:** Hydroxychloroquine

## Key facts

- **NCT ID:** NCT01480154
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2011-11-23
- **Primary completion:** 2020-02-14
- **Final completion:** 2027-03-31
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01480154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01480154, "Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01480154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*